Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia

• Status: Completed
• Trial end date: 2016-05-23
• Target enrollment: 0
• Participant gender: All

Summary

1) to test HDL function comprehensively in healthy and diseased individuals; 2) to evaluate if this test correlates with cardiovascular risk, independent of traditional risk factors; 3) and to differentiate effects of lipid-modifying or antiatherosclerotic drugs on HDL function and composition

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yonsei University
• Treatments: Atorvastatin; Atorvastatin Calcium; Cholestyramine Resin; Ezetimibe

Criteria

Inclusion Criteria:

• The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy

• Aged over 20

• Consent form signed

Exclusion Criteria:

• pregnant or lactating women

• subjects with familial hypercholesterolemia

• uncontrolled hypertension or DM

• Thyroid dysfunction

• Active liver disease (transaminase or bilirubin > 1.5 x NL)

• Serum creatinine > 2 mg/dL

• Included in other clinical trials within 3 months

• using of other medication: fish oil, fibric acid derivatives, niacin, systemic corticosteroid, thiazolidinedione